As companies eye opportunities to invest in and locate new business, technology, and cutting-edge R&D in China, the implementation of the Third Amendment to China’s patent law will have a significant impact on your business transactions and IP portfolio management.
This Foley Web conference in our Global Marketplace — Eye on China: Web Series, explored how companies can successfully implement and integrate IP and business strategies in light of the changes brought about by the Third Amendment.
Specific topics included:
- Promoting increased technology R&D in China — Does the Third Amendment aid or impede this trend?
- The import/export of technology to/from China through licensing or sale transactions: What new issues will arise in the wake of the Third Amendment?
- Protecting IP through nondisclosure agreements and noncompete provisions in labor law
- Will the Third Amendment stimulate further development of the manufacturing sector in China?
Moderator:
- Catherine Sun: Foley Shanghai Office Managing Partner and Asia Practice Chair
Speakers:
- Roger Martin: Qualcomm Senior Vice President and Chief IP Strategist
- Jon W. Dudas: Foley Partner and former Under Secretary of Commerce for Intellectual Property and Director of the USPTO
- Ken Duck: Foley Senior Counsel and member of the firm’s China and International practices and Automotive Industry Team
- Yan Zhao: Foley Senior Counsel and member of the firm’s International and Electronics practices and Automotive Industry Team
Related Insights
June 3, 2025
Foley Corporate Governance Update
Texas Senate Bill 2337: Protecting Texas Companies and Their Directors, Shareholders and Boards from Proxy Advice Not in the Financial Interests of Shareholders
On June 2, 2025, the Texas Legislature passed Senate Bill 2337, meaningfully regulating proxy advisors like ISS and Glass Lewis when providing proxy voting recommendations concerning Texas companies.
September 25, 2025
Events
Unclaimed Property Roundtable with Delaware State Escheator and Leading Practitioners
June 3, 2025
Health Care Law Today
GLP-1 Receptor Agonists: The Surge of M&A Activity and the Future of Metabolic Health
Over the past decade, the global pharmaceutical industry has witnessed a transformation in the treatment landscape for metabolic disorders, particularly type 2 diabetes and obesity.